Aurinia Pharmaceuticals Inc. (AUPH) Guidance & Earnings Results
On 2026-08-06 Aurinia Pharmaceuticals Inc. reaffirmed guidance: "2026 total revenue $315-325M; net product sales…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AUPHAurinia Pharmaceuticals Inc.Follow AUPH — free
—
Price chart with a free account
- Market cap
- 2.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 6 Aug 26 | Reaffirmed | 2026 total revenue $315-325M; net product sales $305-315M · full year |
| 7 May 26 | Reaffirmed | 2026 total revenue $315-325M; net product sales $305-315M · full year |
| 26 Feb 26 | Raised | FY2026 total revenue guidance $315-325M (11-15% growth); net product sales $305-315M (12-16% growth) |
| 4 Nov 25 | Raised | FY2025 total revenue guidance raised to $275-280M, LUPKYNIS sales guidance raised to $265-270M · full year |
| 31 Jul 25 | Raised | FY2025 total revenue raised to $260-270M from $250-260M; FY2025 net product sales raised to $250-260M from $240-250M · full year |
Aurinia Pharmaceuticals Inc. — questions
- What guidance did Aurinia Pharmaceuticals Inc. give?
- On 2026-08-06: "2026 total revenue $315-325M; net product sales $305-315M"
- When does Aurinia Pharmaceuticals Inc. report earnings?
- Aurinia Pharmaceuticals Inc.'s next earnings report is expected on 2026-10-29.
Every figure on this page comes from Aurinia Pharmaceuticals Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.